Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bleomycin induced flagellate erythema].

M Mseddi1, H Hadj Taieb, W Abdelmaksoud

  • 1Service de Dermatologie CHU H. Chaker, Sfax, Tunisie.

Revue Medicale De Liege
|December 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

STSM 2025 & 2nd African Medical Writing Congress.

La Tunisie medicale·2026
Same author

Abstracts Association Tunisienne de Médecine Néonatale (ATMN).

La Tunisie medicale·2026
Same author

Predictive factors for non-response to intravitreal bevacizumab in diabetic macular edema.

Journal francais d'ophtalmologie·2026
Same author

Photic maculopathy: OCT-angiography features of eight eyes.

Archivos de la Sociedad Espanola de Oftalmologia·2025
Same author

Very short-term efficacy of selective laser trabeculoplasty in primary open-angle glaucoma.

Journal francais d'ophtalmologie·2025
Same author

Assessment of optic nerve head microvascular changes with OCT angiography in diabetic patients without diabetic retinopathy.

Journal francais d'ophtalmologie·2025

Bleomycin, an antineoplastic antibiotic, can cause flagellate erythema, a specific skin reaction. This case highlights a patient with Kaposi sarcoma who developed linear lesions after bleomycin treatment.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Bleomycin is a widely used antibiotic with antineoplastic properties, employed in treating various malignancies.
  • Cutaneous toxicity is a known side effect of bleomycin therapy, manifesting in diverse dermatological alterations.
  • Kaposi sarcoma is a condition for which bleomycin is a potential therapeutic agent.

Observation:

  • A 57-year-old female patient with Kaposi sarcoma received bleomycin treatment.
  • Within six days of the initial bleomycin dose, the patient developed distinct linear skin lesions.
  • These lesions were clinically identified as flagellate erythema.

Findings:

  • Flagellate erythema represents a specific cutaneous reaction associated with bleomycin administration.

Related Experiment Videos

  • The occurrence of this reaction appears to be independent of the bleomycin dose, route of administration, or the specific cancer being treated.
  • This adverse event is observed in a significant percentage of patients, estimated between 10% and 35%.

    • Implications:

    • Clinicians should be vigilant for flagellate erythema as a potential side effect in patients undergoing bleomycin therapy.
    • Early recognition and diagnosis of this specific dermatosis can aid in patient management and potentially inform treatment adjustments.
    • Understanding the incidence and characteristics of bleomycin-induced flagellate erythema is crucial for patient counseling and risk assessment in oncological care.